Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | mTOR Inhibition for Cancer Therapy: Past, Present and Future

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Mita, Monica, Mita, Alain, Rowinsky, Eric K. (Eds.)

2015, Approx. 400 p. 15 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 

ISBN 978-2-8178-0492-7

digitally watermarked, no DRM

The eBook version of this title will be available soon


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
approx. $189.00

(net) price for USA

ISBN 978-2-8178-0491-0

free shipping for individuals worldwide

Due: July 8, 2015


add to marked items

  • First book on that topic
  • Input and perspectives by international leaders​
  • Preclinical and clinical data available on the subject have been integrated
  • A dedicated chapter on toxicity profile of mTOR inhibitors
  • Future directions for the development of mTOR inhibitors

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Content Level » Professional/practitioner

Keywords » Akt - cancer - mTOR - rapamycin

Related subjects » Internal Medicine - Molecular Medicine - Oncology & Hematology

Table of contents 

Forward.- Past.- mTOR inhibitors: a little bit of history.- Present.- The mTOR pathway .- The evolving role of mTOR inhibitors in renal cell carcinoma.- The role of mTOR inhibitors in breast cancer.- The role of mTOR inhibitors in neuroendocrine tumors.- New indications of mTOR inhibitors in rare tumors.- The role of mTOR inhibitors in the treatment of hematological malignancies.- The clinical pharmacology and  toxicity profile of rapalogs.- Resistance to mTOR inhibitors.- Rational combinations of mTOR inhibitors as anticancer strategies.- Future.- Predictive biomarkers of response to mTOR inhibitors.- The potential future indication of rapamycin analogs for the treatment of other solid tumors.- mTOR inhibition beyond rapalogs.- mTOR, aging and cancer: the missing link?.- New study design for mTOR inhibitors and other biological agents.- Future directions for the development of mTOR inhibitors.​

Popular Content within this publication 

 

Articles

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Oncology.